EUCTR2004-001101-10-IT进行中（未招募）不适用
A prospective, multicenter, randomized phase III study to evaluate the efficacy of ZOMETA (zoledronic acid) in preventing or delaying of bone metastasis in patients with Stage III non-small cell lung cancer
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
A prospective, multicenter, randomized phase III study to evaluate the efficacy of Zometa (zoledronic acid) in delaying of progression or recurrences in patients with stage III non-small cell lung cancerPatients with unresectable stage IIIA and IIIB Non small cell lung cancer (NSCLC) without bone metastasesEUCTR2004-001101-10-GBovartis Pharmaceuticals UK Ltd446
进行中（未招募）
不适用
A prospective, multicenter, randomized phase III study to evaluate the efficacy of Zometa (zoledronic acid) in delaying progression or recurrence in patients with stage III non-small cell lung cancerEUCTR2004-001101-10-HUovartis Pharma Services AG446
进行中（未招募）
不适用
A prospective, multicenter, randomized phase III study to evaluate the efficacy of Zometa (zoledronic acid) in delaying progression or recurrence in patients with stage III non-small cell lung cancerPatients with unresectable stage IIIA and IIIB Non small cell lung cancer (NSCLC) without bone metastasesEUCTR2004-001101-10-BEovartis Pharma Services AG446
进行中（未招募）
不适用
A prospective, multicenter, randomized phase III study to evaluate the efficacy of Zometa (zoledronic acid) in delaying progression or recurrence in patients with stage III non-small cell lung cancerPatients with unresectable stage IIIA and IIIB Non small cell lung cancer (NSCLC) without bone metastasesEUCTR2004-001101-10-ATovartis Pharma Services AG446
进行中（未招募）
不适用
A prospective, multicenter, randomized phase III study to evaluate the efficacy of Zometa (zoledronic acid) in preventing or delaying of bone metastasis in patients with stage III non-small cell lung cancerPatients with unresectable stage IIIA and IIIB Non small cell lung cancer (NSCLC) without bone metastasesEUCTR2004-001101-10-ESovartis Farmacéutica, S.A446